secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000899923-24-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q4 2023 revenue $197M (+11% YoY); adjusted EPS $0.04; raises FY2024 revenue guidance
--------------------------------------------------------------------------------

- Q4 revenue $196.6M (+11% YoY); full-year 2023 revenue $753.2M (+11% YoY).
- Q4 GAAP EPS $(0.36); adjusted EPS $0.04, first positive adjusted EPS in recent quarters.
- Q4 Hereditary Cancer revenue $88.9M (+5% YoY); Prenatal $40.0M (+37% YoY); GeneSight $35.6M (+11% YoY).
- FY2024 revenue guidance raised to $820-840M (9-11% growth); adjusted EPS guidance $0.00-$0.05.
- Acquired select assets from Intermountain Precision Genomics in Feb 2024, including Precise Tumor and Liquid tests.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000014/0000899923-24-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000014/mygn-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000899923-24-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer